Market overview
The global fill finish market is worth USD 17.6 bn in 2026 and is forecast to reach USD 41.7 bn by 2036, growing at a 9.0% CAGR. United States is the largest country market and Vials is the largest by container segment.
| Scope | Aseptic fill and finish of sterile drug products into vials, syringes and cartridges, including contract fill services, filling lines and closure systems. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 16.0 bn |
| Value 2026 | USD 17.6 bn |
| Value 2036 | USD 41.7 bn |
| CAGR 2026-2036 | 9.0% |
| Volume 2026 | 21,782 million units |
| Volume 2036 | 46,682 million units |
| Average price 2026 | USD 0.81 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Fill Finish market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 17.6 bn |
| 2027 | USD 19.2 bn |
| 2028 | USD 20.9 bn |
| 2029 | USD 22.8 bn |
| 2030 | USD 24.8 bn |
| 2031 | USD 27.1 bn |
| 2032 | USD 29.5 bn |
| 2033 | USD 32.2 bn |
| 2034 | USD 35.1 bn |
| 2035 | USD 38.2 bn |
| 2036 | USD 41.7 bn |
Fill Finish market segmentation
By container
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Vials | 46.0% | 41.7% | USD 8.1 bn | 7.9% |
| Prefilled syringes | 28.0% | 30.5% | USD 4.9 bn | 9.9% |
| Cartridges and pens | 14.0% | 17.4% | USD 2.5 bn | 11.4% |
| Other | 12.0% | 10.4% | USD 2.1 bn | 7.4% |
By offering
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Contract fill-finish services | 46.0% | 50.0% | USD 8.1 bn | 9.9% |
| Filling and inspection equipment | 30.0% | 27.2% | USD 5.3 bn | 7.9% |
| Components and consumables | 24.0% | 22.8% | USD 4.2 bn | 8.4% |
By product
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Biologics | 54.0% | 62.0% | USD 9.5 bn | 10.5% |
| Vaccines | 18.0% | 15.7% | USD 3.2 bn | 7.5% |
| Small molecule injectables | 28.0% | 22.3% | USD 4.9 bn | 6.5% |
By technology
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Conventional cleanroom filling | 30.0% | 20.0% | USD 5.3 bn | 4.7% |
| Restricted-access barrier systems | 34.0% | 32.0% | USD 6.0 bn | 8.3% |
| Isolator-based filling | 36.0% | 48.0% | USD 6.3 bn | 12.2% |
By batch scale
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Clinical | 28.0% | 28.0% | USD 4.9 bn | 9.0% |
| Commercial | 52.0% | 50.0% | USD 9.2 bn | 8.6% |
| Small-batch and personalised | 20.0% | 22.0% | USD 3.5 bn | 10.0% |
Top 25 countries for fill finish by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 82.5% of 2026 revenue and the 25 countries below together hold 95.6%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 6.0 bn | 34.0% | USD 13.7 bn | 8.6% |
| 2 | China | USD 1.6 bn | 9.0% | USD 4.7 bn | 11.6% |
| 3 | Germany | USD 1.4 bn | 8.0% | USD 3.1 bn | 8.2% |
| 4 | India | USD 1.1 bn | 6.0% | USD 2.9 bn | 10.7% |
| 5 | Switzerland | USD 880 mn | 5.0% | USD 1.9 bn | 8.1% |
| 6 | Ireland | USD 792 mn | 4.5% | USD 1.8 bn | 8.8% |
| 7 | Japan | USD 792 mn | 4.5% | USD 1.5 bn | 6.6% |
| 8 | United Kingdom | USD 704 mn | 4.0% | USD 1.5 bn | 8.2% |
| 9 | South Korea | USD 704 mn | 4.0% | USD 2.0 bn | 11.2% |
| 10 | France | USD 616 mn | 3.5% | USD 1.3 bn | 7.7% |
| 11 | Italy | USD 257 mn | 1.5% | USD 567 mn | 8.2% |
| 12 | Spain | USD 192 mn | 1.1% | USD 425 mn | 8.3% |
| 13 | Netherlands | USD 192 mn | 1.1% | USD 425 mn | 8.3% |
| 14 | Belgium | USD 192 mn | 1.1% | USD 425 mn | 8.3% |
| 15 | Canada | USD 192 mn | 1.1% | USD 425 mn | 8.3% |
| 16 | Singapore | USD 192 mn | 1.1% | USD 529 mn | 10.7% |
| 17 | Denmark | USD 160 mn | 0.9% | USD 354 mn | 8.3% |
| 18 | Sweden | USD 128 mn | 0.7% | USD 283 mn | 8.2% |
| 19 | Brazil | USD 128 mn | 0.7% | USD 354 mn | 10.7% |
| 20 | Austria | USD 128 mn | 0.7% | USD 283 mn | 8.2% |
| 21 | Australia | USD 128 mn | 0.7% | USD 283 mn | 8.2% |
| 22 | Taiwan | USD 128 mn | 0.7% | USD 283 mn | 8.2% |
| 23 | Israel | USD 97 mn | 0.6% | USD 212 mn | 8.2% |
| 24 | Mexico | USD 97 mn | 0.6% | USD 267 mn | 10.7% |
| 25 | Saudi Arabia | USD 97 mn | 0.6% | USD 267 mn | 10.7% |
| Rest of world | USD 771 mn | 4.4% | USD 1.7 bn | 8.2% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Lonza
- Samsung Biologics
- Catalent
- Thermo Fisher Scientific
- Vetter Pharma
- Fresenius Kabi
- WuXi Biologics
- Pfizer CentreOne
Group 2: Regional and specialist players
- Recipharm
- Simtra BioPharma Solutions
- Jubilant HollisterStier
- Syntegon
- Grand River Aseptic Manufacturing
- PCI Pharma Services
- Emergent BioSolutions
- Ajinomoto Bio-Pharma Services
- Bausch+Strobel
- Optima Pharma
Group 3: Emerging and niche players
- Societal CDMO
- Berkshire Sterile Manufacturing
- Cenexi
- BioCentriq
- Nephron Pharmaceuticals
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the fill finish market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 9.0% is calculated from the resulting values.
The market is divided by container, by offering, by product, by technology, by batch scale. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the fill finish market?
The global fill finish market is estimated at USD 16.0 bn in 2025 and USD 17.6 bn in 2026.
How fast will the fill finish market grow?
It is forecast to reach USD 41.7 bn by 2036, a compound annual growth rate of 9.0% from 2026, an increase of USD 24.1 bn.
Which country is the largest market for fill finish?
United States is the largest market by revenue at USD 6.0 bn in 2026, 34.0% of the global total. The three largest countries together hold 51.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 11.6% a year from 2026 to 2036.
Which fill finish segment is largest?
In the by container split, Vials is the largest segment with 46.0% of 2026 revenue.
Who are the leading fill finish companies?
Global leaders include Lonza, Samsung Biologics, Catalent, Thermo Fisher Scientific.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Surgical RoboticsUSD 17.7 bn · 14.0% CAGR
- Metered Dose InhalerUSD 17.9 bn · 5.0% CAGR
- Insulin DeliveryUSD 16.8 bn · 8.0% CAGR
- Downstream ProcessingUSD 16.6 bn · 10.5% CAGR
- Antibody Drug ConjugatesUSD 16.5 bn · 14.5% CAGR
- Next Generation SequencingUSD 16.4 bn · 13.0% CAGR
- Nasal Drug DeliveryUSD 19.1 bn · 6.2% CAGR
- Rare Cardiovascular Disease TherapeuticsUSD 16.1 bn · 9.0% CAGR